Multiple Myeloma By The ASCO Post Staff/July 2024 FDA Approves Daratumumab and Hyaluronidase-fihj With VRd for Multiple Myeloma On July 30, the U.S. Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib, lenalidomide, and ...
The multiple myeloma condition center is a comprehensive resource for clinical news and expert insights on multiple myeloma. Read more at OncLive.
daratumumabsafetyIntroduction: The overall survival of patients with multiple myeloma (MM) has changed dramatically in the last decade. MM remains an incurable plasma cell disorder but immunotherapy with monoclonal antibodies (MoAbs) has emerged as a promising treatment.Cejalvo, Maria J.Ribas, Pazde ...
Daratumumab(HuMax®-CD38)Safety Study in Multiple MyelomaBone and Cancer FoundationBone & Cancer Foundation
Multiple myeloma (MM) is a second ranking hematological malignancy. Despite the fast advancement of new treatments such as bortezormib and daratumumab, MM patients remain incurable and tend to eventually become relapsed and drug-resistant. Development of novel therapies capable of depleting MM cells ...
Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells. Preclinical studies have shown that daratumumab induces MM cell death through several mechanisms, including complement-dependent cytotoxicity (CDC), antibody-dependent...
Both are well tolerated with minimal toxicities. Phase III clinical trials will define optimal combination and place in therapy of daratumumab and elotuzumab. 展开 关键词: monoclonal antibodies immunotherapy multiple myeloma daratumumab elotuzumab treatment refractory relapsed ...
In the MASTER study (NCT03224507), daratumumab+carfilzomib/lenalidomide/dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly diagnosed multiple myeloma (NDMM). In GRIFFIN (NCT02874742), daratumumab+lenalidomide/bortezomib/de
Janssen has submitted a new combination regimen for its blockbuster multiple myeloma drug Darzalex for approval with the FDA and EMA, hoping to give the treatment another edge over emerging competitors
Daratumumab is a monoclonal anti-CD38 antibody that is being increasingly incorporated in treatment regimens of patients with newly diagnosed transplant-eligible multiple myeloma (MM). There have been conflicting results regarding the effect of daratumumab-based treatment regimens on success of hematopoietic...